期刊论文详细信息
Frontiers in Genetics
Gene set variation analysis-based aging and senescence score as a prognostic indicator and therapeutic guide in lung adenocarcinoma
Genetics
Xi He1  Hong Wang2  Tao Lin3  Fangchao Zhao4  Ying Liu5 
[1] Dongguan Marina Bay Central Hospital, Dongguan, China;Tangshan Central Blood Station, Tangshan, China;Tangshan People’s Hospital, Tangshan, China;The Second Hospital of Hebei Medical University, Shijiazhuang, China;Xingtai Third Hospital, Xingtai, China;
关键词: aging;    senescence;    lung adenocarcinoma;    prognosis;    immunotherapy;    tumor microenvironment;   
DOI  :  10.3389/fgene.2023.1176292
 received in 2023-02-28, accepted in 2023-04-12,  发布年份 2023
来源: Frontiers
PDF
【 摘 要 】

Accumulating evidence suggests that aging and senescence play crucial roles in tumorigenesis, cancer progression, and treatment. However, the influence of aging and senescence-related genes (ASRGs) on clinical outcomes and treatment options in lung adenocarcinoma (LUAD) patients remains unknown. Here, we developed an aging and senescence-related scoring system, ASRS, by integrating bulk transcriptome data from 22 LUAD datasets. In 3,243 LUAD samples, higher ASRS scores were associated with poor tumor stage and pathological grade, as well as shorter overall survival, disease-free survival, and recurrence-free survival. Additionally, ASRS was associated with different immune patterns in the tumor microenvironment (TME). Importantly, ASRS was found to predict therapeutic efficacy, with patients having a low ASRS benefiting from immunotherapy and those with a high ASRS responding better to chemotherapy. Therefore, ASRS represents a previously overlooked characteristic of LUAD that can influence patient outcomes and treatment success.

【 授权许可】

Unknown   
Copyright © 2023 Lin, Wang, Liu, Zhao and He.

【 预 览 】
附件列表
Files Size Format View
RO202310102556051ZK.pdf 6153KB PDF download
  文献评价指标  
  下载次数:18次 浏览次数:0次